Meffin P J, Grgurinovich N, Brooks P M, Miners J O, Cochran M, Stranks G
Br J Clin Pharmacol. 1983 Dec;16(6):731-4. doi: 10.1111/j.1365-2125.1983.tb02252.x.
Ranitidine disposition has been studied in 12 patients with renal impairment following 50 mg given intravenously and 150 mg given by mouth on separate occasions. The clearance of ranitidine from plasma (y) was correlated with creatinine clearance (x): y = 10.47 + 0.289x,r2 = 0.751, but there was no significant correlation of creatinine clearance with distribution volume or bioavailability. The mean (s.e. mean) distribution volume was 1.62 (0.08) 1/kg and the mean bioavailability 0.81 (0.05). These data suggest that in order to obtain similar ranitidine plasma concentrations in anephric patients and patients with normal renal function, the maintenance dose in the anephric patients should be 25-30% of that for patients with normal renal function.
已对12名肾功能不全患者进行了雷尼替丁处置的研究,分别在不同时间静脉注射50毫克和口服150毫克雷尼替丁。雷尼替丁从血浆中的清除率(y)与肌酐清除率(x)相关:y = 10.47 + 0.289x,r2 = 0.751,但肌酐清除率与分布容积或生物利用度之间无显著相关性。平均(标准误)分布容积为1.62(0.08)升/千克,平均生物利用度为0.81(0.05)。这些数据表明,为了使无肾患者和肾功能正常患者的雷尼替丁血浆浓度相似,无肾患者的维持剂量应为肾功能正常患者的25 - 30%。